Top

Current Treatment Options in Gastroenterology

Published in:

01-12-2018 | Stomach (P Malfertheiner, Section Editor)

Gastric Cancer: an Evolving Disease

Authors: Minkyo Song, MD, PhD, Charles S. Rabkin, MD, M. Constanza Camargo, PhD

Published in: Current Treatment Options in Gastroenterology | Issue 4/2018

Abstract

Purpose of Review

Prevalence of Helicobacter pylori, the primary risk factor for gastric cancer, is declining globally. Paralleling this trend, gastric cancer incidence is also decreasing. Historically, the populations most affected by this neoplasia have been males, Asians, and groups with low socioeconomic status. This review provides an update on recently published literature regarding changes in gastric cancer epidemiology.

Recent Findings

Gastric cancer incidence trends vary by age, sex, race/ethnicity, and tumor anatomical location. Overall incidence appears to be leveling off among young birth cohorts in Western populations, where H. pylori has declined considerably. The changes are more prominent for females and for tumors arising beyond the esophageal-gastric junction.

Summary

The classical incidence pattern of gastric cancer is evolving. While uncertain, several hypotheses may explain the changing burden of disease. The mix of gastric cancer risk factors appears to be shifting, with H. pylori no longer the sole etiological driver. These changes may eliminate the previous predilection of males and lead to increases in overall gastric cancer rates. Analytical studies addressing known and novel factors related to major societal transitions may provide clues to understanding re-emergence of this serious public health problem.

The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9. https://doi.org/10.1038/nature13480.CrossRef

de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin N Am. 2013;42(2):219–40. https://doi.org/10.1016/j.gtc.2013.01.003.CrossRef

Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49(3):347–53.CrossRef

Chen Y, Liu L, Wang X, Wang J, Yan Z, Cheng J, et al. Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies. Cancer Epidemiol Biomark Prev : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013;22(8):1395–408. https://doi.org/10.1158/1055-9965.EPI-13-0042.CrossRef

Shakeri R, Malekzadeh R, Nasrollahzadeh D, Pawlita M, Murphy G, Islami F, et al. Multiplex H. pylori serology and risk of gastric cardia and noncardia adenocarcinomas. Cancer Res. 2015;75(22):4876–83. https://doi.org/10.1158/0008-5472.CAN-15-0556.CrossRefPubMedPubMedCentral

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. https://doi.org/10.3322/caac.21492.

Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22(2):283–97.CrossRefPubMed

• Blaser MJ. The theory of disappearing microbiota and the epidemics of chronic diseases. Nat Rev Immunol. 2017;17(8):461–3. https://doi.org/10.1038/nri.2017.77 An update of the disappearing microbiota hypothesis and potential implications for health and disease.CrossRefPubMed

Olefson S, Moss SF. Obesity and related risk factors in gastric cardia adenocarcinoma. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015;18(1):23–32. https://doi.org/10.1007/s10120-014-0425-4.CrossRef

10.

Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52(24):6735–40.PubMed

11.

Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174. https://doi.org/10.1136/bmj.g3174.CrossRefPubMedPubMedCentral

12.

• Luo G, Zhang Y, Guo P, Wang L, Huang Y, Li K. Global patterns and trends in stomach cancer incidence: age, period and birth cohort analysis. International journal of cancer Journal international du cancer. 2017;141(7):1333–44. https://doi.org/10.1002/ijc.30835 Age-period-cohort analysis of international gastric cancer incidence trends overall.CrossRefPubMed

13.

Aragones N, Goicoa T, Pollan M, Militino AF, Perez-Gomez B, Lopez-Abente G, et al. Spatio-temporal trends in gastric cancer mortality in Spain: 1975-2008. Cancer Epidemiol. 2013;37(4):360–9. https://doi.org/10.1016/j.canep.2013.03.009.CrossRefPubMed

14.

Eom BW, Jung KW, Won YJ, Yang H, Kim YW. Trends in gastric xancer incidence according to the clinicopathological characteristics in Korea, 1999-2014. Cancer Res Treat. 2018. https://doi.org/10.4143/crt.2017.464.CrossRefPubMedPubMedCentral

15.

Song M, Kang D, Yang JJ, Choi JY, Sung H, Lee Y, et al. Age and sex interactions in gastric cancer incidence and mortality trends in Korea. Gastric Cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015;18(3):580–9. https://doi.org/10.1007/s10120-014-0411-x.CrossRef

16.

Holster IL, Aarts MJ, Tjwa ET, Lemmens VE, Kuipers EJ. Trend breaks in incidence of non-cardia gastric cancer in the Netherlands. Cancer Epidemiol. 2014;38(1):9–15. https://doi.org/10.1016/j.canep.2013.11.001.CrossRefPubMed

17.

Castro C, Peleteiro B, Bento MJ, Lunet N. Trends in gastric and esophageal cancer incidence in northern Portugal (1994-2009) by subsite and histology, and predictions for 2015. Tumori. 2017;103(2):155–63. https://doi.org/10.5301/tj.5000542.CrossRefPubMed

18.

•• Anderson WF, Rabkin CS, Turner N, Fraumeni JF, Jr., Rosenberg PS, Camargo MC. The changing face of noncardia gastric cancer incidence among US non-Hispanic whites. Journal of the National Cancer Institute. 2018. doi:https://doi.org/10.1093/jnci/djx262. Age-period-cohort analysis of US gastric cancer incidence trends by anatomic subsite, reporting a new pattern of noncardia gastric cancer.CrossRefPubMedPubMedCentral

19.

Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128(7):765–70. https://doi.org/10.1043/1543-2165(2004)128<765:DTITIA>2.0.CO;2.CrossRefPubMed

20.

Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009;18(7):1945–52. https://doi.org/10.1158/1055-9965.EPI-09-0250.CrossRef

21.

Kaneko S, Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989. Br J Cancer. 2001;84(3):400–5. https://doi.org/10.1054/bjoc.2000.1602.CrossRefPubMedPubMedCentral

22.

Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol. 2010;105(3):493–8. https://doi.org/10.1038/ajg.2009.728.CrossRefPubMedPubMedCentral

23.

Zullo A, Hassan C, Romiti A, Giusto M, Guerriero C, Lorenzetti R, et al. Follow-up of intestinal metaplasia in the stomach: when, how and why. World journal of gastrointestinal oncology. 2012;4(3):30–6. https://doi.org/10.4251/wjgo.v4.i3.30.CrossRefPubMedPubMedCentral

24.

Liu CY, Wu CY, Lin JT, Lee YC, Yen AM, Chen TH. Multistate and multifactorial progression of gastric cancer: results from community-based mass screening for gastric cancer. J Med Screen. 2006;13(Suppl 1):S2–5.PubMed

25.

•• Huang KK, Ramnarayanan K, Zhu F, Srivastava S, Xu C, Tan ALK, et al. Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer. Cancer Cell. 2018;33(1):137–50 e5. https://doi.org/10.1016/j.ccell.2017.11.018 Comprehensive molecular characterization of subtypes of gastric intestinal metaplasia.CrossRefPubMed

26.

Gonzalez CA, Sanz-Anquela JM, Gisbert JP, Correa P. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. International journal of cancer Journal international du cancer. 2013;133(5):1023–32. https://doi.org/10.1002/ijc.28003.CrossRefPubMed

27.

Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O’Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44(1):74–94. https://doi.org/10.1055/s-0031-1291491.CrossRefPubMed

28.

Haruma K, Kamada T, Murao T, Yamanaka Y, Ohsawa M, Shiotani A, et al. European guideline for the management of precancerous conditions in the stomach and it’s application to Japan. Nihon Rinsho. 2013;71(8):1479–84.PubMed

29.

Marques-Silva L, Areia M, Elvas L, Dinis-Ribeiro M. Prevalence of gastric precancerous conditions: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2014;26(4):378–87. https://doi.org/10.1097/MEG.0000000000000065.CrossRefPubMed

30.

Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161–81.CrossRefPubMed

31.

Imai T, Murayama H. Time trend in the prevalence of intestinal metaplasia in Japan. Cancer-Am Cancer Soc. 1983;52(2):353–61.

32.

Sipponen P, Kimura K. Intestinal metaplasia, atrophic gastritis and stomach cancer: trends over time. Eur J Gastroenterol Hepatol. 1994;6(Suppl 1):S79–83.PubMed

33.

Yee YK, Wong KW, Hui CK, Chan CK, Chan AO, Lam SK, et al. Prevalence and time trend of intestinal metaplasia in Hong Kong. J Gastroenterol Hepatol. 2009;24(5):896–9. https://doi.org/10.1111/j.1440-1746.2009.05799.x.CrossRefPubMed

34.

de Vries AC, Meijer GA, Looman CW, Casparie MK, Hansen BE, van Grieken NC, et al. Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands. Gut. 2007;56(12):1665–70. https://doi.org/10.1136/gut.2007.127167.CrossRefPubMedPubMedCentral

35.

Guarner J, Bartlett J, Whistler T, Pierce-Smith D, Owens M, Kreh R, et al. Can pre-neoplastic lesions be detected in gastric biopsies of children with Helicobacter pylori infection? J Pediatr Gastroenterol Nutr. 2003;37(3):309–14.CrossRefPubMed

36.

Camacho-Gomez SM, Bernieh A, Saad AG, Tipnis NA. Non-Helicobacter pylori gastric intestinal metaplasia in children: a series of cases and review of the literature. Case Rep Gastrointest Med. 2018;2018:5930415. https://doi.org/10.1155/2018/5930415.CrossRefPubMedPubMedCentral

37.

Minalyan A, Benhammou JN, Artashesyan A, Lewis MS, Pisegna JR. Autoimmune atrophic gastritis: current perspectives. Clin Exp Gastroenterol. 2017;10:19–27. https://doi.org/10.2147/CEG.S109123.CrossRefPubMedPubMedCentral

38.

Bizzaro N, Antico A. Diagnosis and classification of pernicious anemia. Autoimmun Rev. 2014;13(4–5):565–8. https://doi.org/10.1016/j.autrev.2014.01.042.CrossRefPubMed

39.

Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis--pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013;10(9):529–41. https://doi.org/10.1038/nrgastro.2013.101.CrossRefPubMed

40.

Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347(12):911–20. https://doi.org/10.1056/NEJMra020100.CrossRefPubMed

41.

• Song H, Held M, Sandin S, Rautelin H, Eliasson M, Soderberg S, et al. Increase in the prevalence of atrophic gastritis among adults age 35 to 44 years old in northern Sweden between 1990 and 2009. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015;13(9):1592–600 e1. https://doi.org/10.1016/j.cgh.2015.04.001 A serosurvey documenting an increasing prevalence of corpus extension atrophic gastritis in young individuals.CrossRef

42.

Smyk DS, Koutsoumpas AL, Mytilinaiou MG, Rigopoulou EI, Sakkas LI, Bogdanos DP. Helicobacter pylori and autoimmune disease: cause or bystander. World journal of gastroenterology : WJG. 2014;20(3):613–29. https://doi.org/10.3748/wjg.v20.i3.613.CrossRefPubMedPubMedCentral

43.

Parsons BN, Ijaz UZ, D’Amore R, Burkitt MD, Eccles R, Lenzi L, et al. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. PLoS Pathog. 2017;13(11):e1006653. https://doi.org/10.1371/journal.ppat.1006653.CrossRefPubMedPubMedCentral

44.

Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009. PLoS One. 2013;8(2):e56060. https://doi.org/10.1371/journal.pone.0056060.CrossRefPubMedPubMedCentral

45.

Kuipers EJ. Proton pump inhibitors and Helicobacter pylori gastritis: friends or foes? Basic Clin Pharmacol Toxicol. 2006;99(3):187–94. https://doi.org/10.1111/j.1742-7843.2006.pto_478.x.CrossRefPubMed

46.

Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The gastric and intestinal microbiome: role of proton pump inhibitors. Curr Gastroenterol Rep. 2017;19(8):42. https://doi.org/10.1007/s11894-017-0577-6.CrossRefPubMedPubMedCentral

47.

Wennerström ECM, Simonsen J, Camargo MC, Rabkin CS. Acid-suppressing therapies and subsite-specific risk of stomach cancer. Br J Cancer. 2017;116(9):1234–8. https://doi.org/10.1038/bjc.2017.84.CrossRefPubMedPubMedCentral

48.

Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137(3):824–33. https://doi.org/10.1053/j.gastro.2009.05.001.CrossRefPubMed

49.

Hruby A, Hu FB. The epidemiology of obesity: a big picture. PharmacoEconomics. 2015;33(7):673–89. https://doi.org/10.1007/s40273-014-0243-x.CrossRefPubMedPubMedCentral

50.

Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur J Cancer. 2009;45(16):2867–73. https://doi.org/10.1016/j.ejca.2009.04.019.CrossRefPubMed

51.

Camargo MC, Freedman ND, Hollenbeck AR, Abnet CC, Rabkin CS. Height, weight, and body mass index associations with gastric cancer subsites. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2014;17(3):463–8. https://doi.org/10.1007/s10120-013-0312-4.CrossRef

52.

Sipponen P, Correa P. Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2002;5(4):213–9. https://doi.org/10.1007/s101200200037.CrossRef

53.

Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012;21(1):20–38. https://doi.org/10.1158/1055-9965.EPI-11-0834.CrossRef

54.

Nichols HB, Trentham-Dietz A, Hampton JM, Titus-Ernstoff L, Egan KM, Willett WC, et al. From menarche to menopause: trends among US women born from 1912 to 1969. Am J Epidemiol. 2006;164(10):1003–11. https://doi.org/10.1093/aje/kwj282.CrossRefPubMed

55.

Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest. 2009;119(9):2475–87. https://doi.org/10.1172/JCI38605.CrossRefPubMedPubMedCentral

Title: Gastric Cancer: an Evolving Disease
Authors: Minkyo Song, MD, PhD
Charles S. Rabkin, MD
M. Constanza Camargo, PhD
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Treatment Options in Gastroenterology / Issue 4/2018
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-018-0203-1

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2018

Gastroduodenal “Dysbiosis”: a New Clinical Entity

Update on Vaccinating the Patient With Inflammatory Bowel Disease

Migraine, Cyclic Vomiting Syndrome, and Other Gastrointestinal Disorders

The Role of Botulinum Toxin Injections for Esophageal Motility Disorders

Timing of Endoscopic Necrosectomy Following Transmural Stent Placement for Pancreatic Necrosis

Opioid-Induced Esophageal Dysfunction: An Emerging Entity with Sweeping Consequences

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage